Tocilizumab in Patients Infected by SARS-CoV2

Overview

Journal Med Clin (Engl Ed)

Date 2021 Mar 25

PMID 33763598

Authors

Milagros Sancho

Javier Muniz

Pablo Cardinal-Fernandez

Affiliations

Soon will be listed here.

Citing Articles

Epidemiology of the COVID-19 pneumonia in a group of hospitals from Madrid-Spain during the full period of the State of Alarm HM cohort.

Barberan J, Ramos M, Villanueva J, Villarez P, Villares P, Villareal M Rev Esp Quimioter. 2025; 38(2):97-107.

PMID: 39950446 PMC: 11894567. DOI: 10.37201/req/110.2024.

References

Bernard G, Francois B, Mira J, Vincent J, Dellinger R, Russell J . Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*. Crit Care Med. 2013; 42(3):504-11. DOI: 10.1097/CCM.0000000000000043. View

Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F . Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020; 19(7):102568. PMC: 7252115. DOI: 10.1016/j.autrev.2020.102568. View

Zhao J, Cui W, Tian B . Efficacy of tocilizumab treatment in severely ill COVID-19 patients. Crit Care. 2020; 24(1):524. PMC: 7450680. DOI: 10.1186/s13054-020-03224-7. View

Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M . Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002; 288(1):49-57. DOI: 10.1001/jama.288.1.49. View

Salvarani C, Dolci G, Massari M, Merlo D, Cavuto S, Savoldi L . Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2020; 181(1):24-31. PMC: 7577199. DOI: 10.1001/jamainternmed.2020.6615. View

Zhu J, Pang J, Ji P, Zhong Z, Li H, Li B . Elevated interleukin-6 is associated with severity of COVID-19: A meta-analysis. J Med Virol. 2020; 93(1):35-37. PMC: 7283812. DOI: 10.1002/jmv.26085. View

Marti-Carvajal A, Simancas-Racines D, Anand V, Bangdiwala S . Prophylactic lidocaine for myocardial infarction. Cochrane Database Syst Rev. 2015; (8):CD008553. PMC: 8454263. DOI: 10.1002/14651858.CD008553.pub2. View

Biran N, Ip A, Ahn J, Go R, Wang S, Mathura S . Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol. 2020; 2(10):e603-e612. PMC: 7428303. DOI: 10.1016/S2665-9913(20)30277-0. View

Opal S, Fisher Jr C, Dhainaut J, Vincent J, Brase R, Lowry S . Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med. 1997; 25(7):1115-24. DOI: 10.1097/00003246-199707000-00010. View

10.

Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez A . Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003; 290(2):238-47. DOI: 10.1001/jama.290.2.238. View

11.

Singh J, Beg S, Lopez-Olivo M . Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol. 2010; 38(1):10-20. DOI: 10.3899/jrheum.100717. View

12.

Somers E, Eschenauer G, Troost J, Golob J, Gandhi T, Wang L . Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19. Clin Infect Dis. 2020; 73(2):e445-e454. PMC: 7454462. DOI: 10.1093/cid/ciaa954. View

13.

Stone J, Frigault M, Serling-Boyd N, Fernandes A, Harvey L, Foulkes A . Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020; 383(24):2333-2344. PMC: 7646626. DOI: 10.1056/NEJMoa2028836. View

14.

Abraham E, Glauser M, Butler T, Garbino J, Gelmont D, Laterre P . p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA. 1997; 277(19):1531-8. View

15.

Aziz M, Fatima R, Assaly R . Elevated interleukin-6 and severe COVID-19: A meta-analysis. J Med Virol. 2020; 92(11):2283-2285. PMC: 7267383. DOI: 10.1002/jmv.25948. View

16.

Fu B, Xu X, Wei H . Why tocilizumab could be an effective treatment for severe COVID-19?. J Transl Med. 2020; 18(1):164. PMC: 7154566. DOI: 10.1186/s12967-020-02339-3. View

17.

Soraya G, Ulhaq Z . Crucial laboratory parameters in COVID-19 diagnosis and prognosis: An updated meta-analysis. Med Clin (Engl Ed). 2020; 155(4):143-151. PMC: 7442896. DOI: 10.1016/j.medcle.2020.05.004. View

18.

Rosas I, Brau N, Waters M, Go R, Hunter B, Bhagani S . Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N Engl J Med. 2021; 384(16):1503-1516. PMC: 7953459. DOI: 10.1056/NEJMoa2028700. View

19.

Sinha P, Matthay M, Calfee C . Is a "Cytokine Storm" Relevant to COVID-19?. JAMA Intern Med. 2020; 180(9):1152-1154. DOI: 10.1001/jamainternmed.2020.3313. View

20.

Han H, Ma Q, Li C, Liu R, Zhao L, Wang W . Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020; 9(1):1123-1130. PMC: 7473317. DOI: 10.1080/22221751.2020.1770129. View